BioneerCorp
KOSDAQ:064550
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioneerCorp
Cash & Cash Equivalents
BioneerCorp
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioneerCorp
KOSDAQ:064550
|
Cash & Cash Equivalents
₩46.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
19%
|
|
|
Celltrion Inc
KRX:068270
|
Cash & Cash Equivalents
₩1.1T
|
CAGR 3-Years
27%
|
CAGR 5-Years
10%
|
CAGR 10-Years
22%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Cash & Cash Equivalents
₩6.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Cash & Cash Equivalents
₩10.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash & Cash Equivalents
₩66.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
25%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Cash & Cash Equivalents
₩112B
|
CAGR 3-Years
65%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
BioneerCorp
Glance View
BIONEER Corp. engages in the manufacture and sale of biotechnological products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2005-12-29. The firm mainly focuses on the development of deoxyribonucleic acid (DNA) reagents, molecular diagnostic kits and other services, such as DNA and ribonucleic acid (RNA) amplification products, Oligo synthesis and reagents, gene synthesis services, gene expressions, protein expressions and purifications, genomics services, human diagnostics kits, veterinary diagnostics kits and others. The company also provides DNA devices, including DNA extraction, amplification and quantitative analysis devices and other DNA diagnostic devices, and supplies for tests and others. In addition, it provides equipment and supplies used for biotechnology research. The firm operates its business within domestic market and in overseas markets, including America, China, Japan, India, Africa and others.
See Also
What is BioneerCorp's Cash & Cash Equivalents?
Cash & Cash Equivalents
46.1B
KRW
Based on the financial report for Dec 31, 2025, BioneerCorp's Cash & Cash Equivalents amounts to 46.1B KRW.
What is BioneerCorp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
19%
The average annual Cash & Cash Equivalents growth rates for BioneerCorp have been 2% over the past three years , 7% over the past five years , and 19% over the past ten years .
